1. Prior treatment with gemcitabine, carboplatin (except in the adjuvant setting), or Iniparib. 
2. Past or current history of neoplasm other than the entry diagnosis, with the exception of treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences. 
3. A history of cardiac disease, as defined by: 
Malignant hypertension 
Unstable angina 
Congestive heart failure 
Myocardial infarction within the previous 6 months 
Symptomatic, unstable or uncontrolled, cardiac arrhythmias. Patients who have stable, rate-controlled atrial fibrillation are eligible for study enrollment. 
4. Active brain metastases. Patients with treated brain metastases are eligible, if (1) radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids. 
5. Women who are pregnant or lactating. 
6. Any serious, active infection (> Grade 2) at the time of treatment. 
7. A serious underlying medical condition that would impair the ability of the patient to receive protocol treatment. 
8. A major surgical procedure, or significant traumatic injury ≤28 days of beginning treatment, or anticipation of the need for major surgery during the course of the study. 
9. Uncontrolled or intercurrent illness including, that in the opinion of the investigator may increase the risks associated with study participation or administration of the investigational products, or that may interfere with the interpretation of the results. 
10. History of any medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results. 
11. Known or suspected allergy/hypersensitivity to any agent given in the course of this trial. 
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.       
    

NCT01082549_exc_T1
Drug
gemcitabine
NCT01082549_exc_T2
Drug
carboplatin
NCT01082549_exc_T3
Drug
Iniparib
NCT01082549_exc_T4
Temporal
Prior
NCT01082549_exc_T5
Scope
gemcitabine, carboplatin (except in the adjuvant setting), or Iniparib
NCT01082549_exc_T6
Condition
neoplasm
NCT01082549_exc_T7
Condition
non-melanoma skin cancer
NCT01082549_exc_T8
Procedure
treated
NCT01082549_exc_T9
Qualifier
treated
NCT01082549_exc_T10
Condition
carcinoma in-situ
NCT01082549_exc_T11
Condition
cancers
NCT01082549_exc_T12
Qualifier
invasive
NCT01082549_exc_T13
Qualifier
treated definitively
NCT01082549_exc_T14
Procedure
treated
NCT01082549_exc_T15
Negation
with the exception of
NCT01082549_exc_T16
Temporal
>5 years previously
NCT01082549_exc_T17
Observation
evidence of recurrences
NCT01082549_exc_T18
Negation
no
NCT01082549_exc_T19
Observation
history
NCT01082549_exc_T20
Temporal
current
NCT01082549_exc_T21
Temporal
Past
NCT01082549_exc_T22
Scope
Past or current
NCT01082549_exc_T23
Qualifier
other than the entry diagnosis
NCT01082549_exc_T24
Condition
entry diagnosis
NCT01082549_exc_T25
Scope
treated non-melanoma skin cancer or carcinoma in-situ of any primary site, or invasive cancers treated definitively, with treatment ending >5 years previously and no evidence of recurrences
NCT01082549_exc_T26
Condition
cardiac disease
NCT01082549_exc_T27
Observation
history
NCT01082549_exc_T29
Condition
Malignant hypertension
NCT01082549_exc_T30
Condition
Unstable angina
NCT01082549_exc_T31
Condition
Congestive heart failure
NCT01082549_exc_T32
Condition
Myocardial infarction
NCT01082549_exc_T33
Temporal
within the previous 6 months
NCT01082549_exc_T34
Condition
cardiac arrhythmias
NCT01082549_exc_T35
Qualifier
uncontrolled
NCT01082549_exc_T36
Qualifier
unstable
NCT01082549_exc_T37
Qualifier
Symptomatic
NCT01082549_exc_T38
Scope
Symptomatic, unstable or uncontrolled
NCT01082549_exc_T39
Condition
atrial fibrillation
NCT01082549_exc_T41
Negation
are eligible
NCT01082549_exc_T42
Qualifier
rate-controlled
NCT01082549_exc_T43
Qualifier
stable
NCT01082549_exc_T44
Condition
brain metastases
NCT01082549_exc_T45
Temporal
Active
NCT01082549_exc_T46
Condition
brain metastases
NCT01082549_exc_T47
Procedure
treated
NCT01082549_exc_T48
Qualifier
treated
NCT01082549_exc_T49
Negation
are eligible
NCT01082549_exc_T51
Procedure
radiation therapy
NCT01082549_exc_T52
Temporal
at least 2 weeks prior to study entry
NCT01082549_exc_T53
Reference_point
study entry
NCT01082549_exc_T54
Condition
disease progression
NCT01082549_exc_T55
Procedure
follow-up scan
NCT01082549_exc_T56
Negation
no
NCT01082549_exc_T57
Drug
steroids
NCT01082549_exc_T58
Negation
not
NCT01082549_exc_T59
Mood
require
NCT01082549_exc_T60
Scope
radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids
NCT01082549_exc_T61
Scope
treated brain metastases
NCT01082549_exc_T62
Scope
treated brain metastases are eligible, if (1) radiation therapy was completed at least 2 weeks prior to study entry; (2) follow-up scan shows no disease progression; and (3) patient does not require steroids
NCT01082549_exc_T63
Condition
pregnant
NCT01082549_exc_T64
Person
Women
NCT01082549_exc_T65
Condition
lactating
NCT01082549_exc_T67
Condition
infection
NCT01082549_exc_T68
Value
> Grade 2
NCT01082549_exc_T69
Qualifier
> Grade 2
NCT01082549_exc_T70
Qualifier
serious
NCT01082549_exc_T71
Temporal
active
NCT01082549_exc_T72
Condition
medical condition
NCT01082549_exc_T73
Qualifier
serious
NCT01082549_exc_T77
Condition
impair the ability of the patient to receive protocol treatment
NCT01082549_exc_T78
Mood
would
NCT01082549_exc_T79
Procedure
surgical procedure
NCT01082549_exc_T80
Qualifier
major
NCT01082549_exc_T82
Qualifier
significant
NCT01082549_exc_T84
Condition
traumatic injury
NCT01082549_exc_T85
Temporal
≤28 days of beginning treatment
NCT01082549_exc_T86
Reference_point
beginning treatment
NCT01082549_exc_T87
Procedure
major surgery
NCT01082549_exc_T88
Mood
need for
NCT01082549_exc_T89
Temporal
during the course of the study
NCT01082549_exc_T90
Reference_point
the course of the study
NCT01082549_exc_T91
Qualifier
Uncontrolled
NCT01082549_exc_T92
Temporal
intercurrent
NCT01082549_exc_T93
Condition
illness
NCT01082549_exc_T94
Qualifier
in the opinion of the investigator may increase the risks
NCT01082549_exc_T96
Scope
Uncontrolled or intercurrent
NCT01082549_exc_T98
Condition
psychiatric condition
NCT01082549_exc_T99
Condition
laboratory abnormality
NCT01082549_exc_T100
Procedure
laboratory
NCT01082549_exc_T102
Condition
hypersensitivity
NCT01082549_exc_T103
Condition
allergy
NCT01082549_exc_T104
Mood
Known
NCT01082549_exc_T105
Mood
suspected
NCT01082549_exc_T106
Scope
Known or suspected
NCT01082549_exc_T107
Drug
agent given in the course of this trial
NCT01082549_exc_T108
Scope
allergy/hypersensitivity